Company Encyclopedia
View More
name
SL PHARM
002038.SZ
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsenic trioxide; thymopentin; paclitaxel injection; docetaxel injection; vinorelbine tartrate injection; asparaginase; calcium folinate; gemcitabine hydrochloride; regorafenib tablets; oseltamivir phosphate capsules; ornidazole injection; adefovir dipivoxil capsules/adefovir dipivoxil tablets; ribavirin; valacyclovir hydrochloride; levofloxacin hydrochlorid; tenofovir disoproxil fumarate; cyclosporin injection/cyclosporin soft capsules; mycophenolate mofetil dispersible; coenzyme complex; enoxaparin sodium; simvastatin; telmisartan amlodipine; liposon; nitroglycerin spray; eptifibatide, argatroban; voglibose; dapagliflozin; vildagliptin; granisetron hydrochloride injection; omeprazole enteric-coated capsules; adenosylmethionine butanedisulfonate; cytidine triphosphate disodium injection cytidine triphosphate disodium injection; gabapentin; risedronate sodium; salmon calcitonin injection; lucosamine sulfate capsules; loratadine dispersible; desloratadine; naftopidil; somatostatin for injection; octreotide acetate; and etodolac sustained-release tablets. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998.
1.587 T
002038.SZMarket value -Rank by Market Cap -/-

Financial Score

15/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking43/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.48%C
    • Profit Margin14.48%B
    • Gross Margin59.35%A
  • Growth ScoreD
    • Revenue YoY-26.04%E
    • Net Profit YoY1.67%C
    • Total Assets YoY1.98%C
    • Net Assets YoY1.11%C
  • Cash ScoreD
    • Cash Flow Margin690.73%C
    • OCF YoY-26.04%E
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreA
    • Gearing Ratio5.44%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SL PHARM: GLP-1 long-acting products are organizing materials in preparation for reporting

    On November 3rd, SL PHARM stated on the interactive platform that the company's GLP-1 long-acting product is currently organizing materials in preparation for submission

    Zhitong·
    SZ
    002038
    -0.66%
    Zhitong·
    SZ
    002038
    -0.66%

    SL PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 141 million yuan, a year-on-year increase of 943.10%

    According to the Zhitong Finance APP, SL PHARM released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 459 million yuan, a year-on-year decrease of 15.13%. The net profit attributable to shareholders of the listed company was 141 million yuan, a year-on-year increase of 943.10%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.3349 million yuan, a year-on-year decrease of 62.39%

    Zhitong·
    SZ
    002038
    -0.66%
    Zhitong·
    SZ
    002038
    -0.66%

    Shuanglu Pharmaceutical's invested company XUANZHUBIO is expected to be listed on the Stock Exchange on October 15

    Shuanglu Pharmaceutical's investee company XUANZHUBIO is expected to be listed on the Stock Exchange on October 15, 2025. XUANZHUBIO is offering a total of 67,333,500 shares globally at a price of HKD 11.60 per share. Shuanglu Pharmaceutical holds 1,780,800 shares, which is expected to account for 0.34% of the total shares after issuance, and will be subject to a lock-up period of 12 months after the listing

    Zhitong·
    HK
    02575
    -12.00%
    Zhitong·
    HK
    02575
    -12.00%

    SL PHARM: The invested company Changfeng Pharmaceutical plans to go public in Hong Kong on October 8

    SL PHARM announced that its associate company Changfeng Pharmaceutical is expected to be listed in Hong Kong on October 8, 2025, with a stock code and a global offering of 41.198 million shares at an issue price of HKD 14.75. SL PHARM holds a 3.68% stake in Changfeng Pharmaceutical, with a lock-up period of 12 months. The listing is expected to have a positive impact on SL PHARM's financial and operational results, and investors should be aware of the risks

    Zhitong·
    SZ
    002038
    -0.66%
    Zhitong·
    SZ
    002038
    -0.66%

    Shuanglu Pharmaceutical's investee company CF PHARMTECH is expected to be listed on the Stock Exchange on October 8

    According to the announcement from Zhitong Finance APP, Shuanglu Pharmaceutical announced that its affiliated company CF PHARMTECH is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025. According to the global offering prospectus of CF PHARMTECH, it will offer 41.198 million shares in this global offering, with a sale price of HKD 14.75 per share

    Zhitong·
    HK
    02652
    +0.73%
    Zhitong·
    HK
    02652
    +0.73%
    © 2025 Longbridge｜Disclaimer